Sánchez-Martín David, Sørensen Morten Dræby, Lykkemark Simon, Sanz Laura, Kristensen Peter, Ruoslahti Erkki, Álvarez-Vallina Luis
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain; Department of Molecular Biology and Genetics, Aarhus University, 8000C Aarhus, Denmark.
Trends Biotechnol. 2015 May;33(5):292-301. doi: 10.1016/j.tibtech.2015.02.008. Epub 2015 Mar 26.
Antibody-based drugs represent one of the most successful and promising therapeutic approaches in oncology. Large combinatorial phage antibody libraries are available for the identification of therapeutic antibodies and various technologies exist for their further conversion into multivalent and multispecific formats optimized for the desired pharmacokinetics and the pathological context. However, there is no technology for antigen profiling of intact tumors to identify tumor markers targetable with antibodies. Such constraints have led to a relative paucity of tumor-associated antigens for antibody targeting in oncology. Here we review novel approaches aimed at the identification of antibody-targetable, accessible antigens in intact tumors. We hope that such advanced selection approaches will be useful in the development of next-generation antibody therapies for cancer.
基于抗体的药物是肿瘤学中最成功且最具前景的治疗方法之一。大型组合噬菌体抗体文库可用于鉴定治疗性抗体，并且存在多种技术可将其进一步转化为针对所需药代动力学和病理背景进行优化的多价和多特异性形式。然而，目前尚无用于完整肿瘤抗原谱分析以鉴定可被抗体靶向的肿瘤标志物的技术。这些限制导致肿瘤学中可用于抗体靶向的肿瘤相关抗原相对较少。在此，我们综述了旨在鉴定完整肿瘤中可被抗体靶向的可及性抗原的新方法。我们希望此类先进的筛选方法将有助于开发下一代癌症抗体疗法。
